Share Facebook
Crohn's Disease Forum » Books, Multimedia, Research & News » VB-201 (Lecinoxoid class of oral anti-inflammatory agents)


05-22-2012, 02:27 AM   #1
Igor_Passau
Forum Monitor
 
Igor_Passau's Avatar
 
Join Date: Aug 2010
Location: Kyiv, Ukraine
VB-201 (Lecinoxoid class of oral anti-inflammatory agents)

About VB-201

VB-201 is a proprietary, first-in-class, orally-available, specific innate immunity disease-modifying medicine in development for the effective treatment of chronic immune-inflammatory diseases. VB-201 offers the potential to deliver long-term control of a spectrum of immune-inflammatory conditions, including psoriasis, rheumatoid arthritis, atherosclerosis and inflammatory bowel disease.

Five Phase 1 clinical trials involving 140 healthy subjects have demonstrated that VB-201 is well tolerated with a favorable safety profile. VBL recently completed a Phase 2 clinical trial for VB-201 in patients with moderate to severe psoriasis. Data from a Phase 2 sub-study of VB-201in psoriasis patients with cardiovascular risk demonstrated a statistically significant reduction in vascular inflammation associated with atherosclerotic lesions as measured by PET-CT imaging. The findings validate the compound's novel mechanism of action for the control and attenuation of chronic immune-inflammatory diseases via highly selective modulation of components of the innate immune system, and demonstrate an anti-inflammatory effect on two systemic inflammatory conditions simultaneously—atherosclerosis of the vascular wall and psoriasis.


About VBL Therapeutics

VBL Therapeutics is an innovative, clinical stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer. VBL has pioneered the Lecinoxoid class of oral anti-inflammatory agents. VB-201 is the company's lead candidate from this program and has currently completed Phase 2 clinical development in patients with psoriasis. In addition, VBL has a proprietary Vascular Targeting System (VTS™) technology platform that has yielded VB-111, a first-in-class, highly-targeted, anti-angiogenic biological agent for the treatment of cancer, which is currently in Phase 2 clinical trials for thyroid cancer and glioblastoma. The company is based in Tel Aviv, Israel. VBL has 70 granted patents and more than 110 patents pending. For more information on the company, please visit

www.vblrx.com
05-22-2012, 02:27 AM   #2
Igor_Passau
Forum Monitor
 
Igor_Passau's Avatar
 
Join Date: Aug 2010
Location: Kyiv, Ukraine
http://www.drugs.com/clinical_trials...ical+Trials%29
05-22-2012, 02:43 AM   #3
Igor_Passau
Forum Monitor
 
Igor_Passau's Avatar
 
Join Date: Aug 2010
Location: Kyiv, Ukraine
lecinoxoid?
Reply

Crohn's Disease Forum » Books, Multimedia, Research & News » VB-201 (Lecinoxoid class of oral anti-inflammatory agents)
Thread Tools


All times are GMT -5. The time now is 10:35 PM.
Copyright 2006-2017 Crohnsforum.com